Table 12.6g

Immunosuppression Use for Maintenance Between Discharge

and One Year Following Transplantation, 1995 to 2004

Recipients with Lung Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 893 836 948 893 922 977 1,083 1,054 1,099 1,185
Tx with Follow-up Immunosuppression Info 634 564 673 626 664 735 804 827 879 976
Corticosteroids Any in Category 99.1% 99.3% 98.2% 99.5% 99.1% 98.6% 99.5% 97.0% 97.8% 99.2%
Steroids 99.1% 99.3% 98.2% 99.5% 99.1% 98.6% 99.5% 97.0% 97.8% 99.2%
Cyclosporine Any in Category 70.7% 69.9% 62.0% 64.1% 63.7% 54.6% 45.9% 35.3% 30.9% 24.7%
Cyclosporin 1.1% 0.0% 0.0% 0.0% 0.0% 0.3% 0.5% 0.1% 0.0% 0.1%
Sandimmmune 35.5% 14.0% 8.0% 6.5% 4.7% 4.2% 5.0% 2.5% 2.6% 1.2%
Neoral 34.1% 55.7% 53.8% 57.5% 58.6% 48.2% 34.0% 26.0% 20.9% 17.8%
Gengraf 0.0% 0.0% 0.1% 0.0% 0.3% 1.9% 6.3% 6.5% 7.2% 5.5%
Eon 0.0% 0.2% 0.0% 0.0% 0.2% 0.0% 0.1% 0.1% 0.2% 0.0%
Tacrolimus Any in Category 23.2% 33.7% 37.7% 41.9% 46.5% 55.6% 69.3% 75.7% 76.2% 83.6%
Tacrolimus 23.2% 33.7% 37.7% 41.9% 46.5% 55.6% 69.3% 75.7% 76.2% 83.6%
Antimetabolites Any in Category 90.5% 88.7% 88.4% 93.0% 91.4% 94.3% 90.7% 88.8% 87.9% 88.4%
Mycophenolate Mofetil 10.6% 19.9% 30.3% 30.4% 33.9% 40.8% 42.3% 45.1% 46.5% 49.1%
Mycophenolate Sodium 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2%
Azathioprine 79.3% 68.4% 57.5% 62.5% 57.5% 53.3% 48.0% 43.7% 41.4% 39.1%
Leflunomide 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0%
Cytoxan 0.6% 0.4% 0.6% 0.2% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0%
mTOR Inhibitors Any in Category 0.0% 0.0% 0.0% 0.3% 6.2% 6.3% 11.1% 14.4% 10.1% 8.5%
Sirolimus 0.0% 0.0% 0.0% 0.2% 5.9% 6.3% 11.1% 14.4% 10.1% 8.5%
Everolimus 0.0% 0.0% 0.0% 0.2% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 1, 2006.

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.